Celgene's profit rises 77.4 pct on Revlimid demand

July 27 (Reuters) - Celgene Corp reported a 77.4 percent rise in quarterly profit on Thursday, helped by higher sales of its flagship cancer drug, Revlimid.

The company's net income rose to $1.06 billion, or $1.31 per share, in the second quarter ended June 30, from $598 million, or 75 cents per share, a year earlier.

Revenue rose 18.7 percent to $3.27 billion.

(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)